aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in aTYR PHARMA INC as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 111
- +28 vs. Q4 2025
- Shares held
- 56.1M
- +6.19M (+12.4%) vs. Q4 2025
- Total value
- $43.7M
- +$5.49M (+14.4%) vs. Q4 2025
- New holders
- 36
- 27 more added
- Sold out
- 8
- 30 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ATYR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 89 | $23.2M |
| Q1 2026 | 111 | $43.7M |
| Q4 2025 | 84 | $42.1M |
| Q3 2025 | 103 | $43.9M |
| Q2 2025 | 110 | $336.5M |
| Q1 2025 | 87 | $186.5M |
| Q4 2024 | 77 | $198.6M |
| Q3 2024 | 56 | $84.3M |
| Q2 2024 | 47 | $75.1M |
| Q1 2024 | 56 | $81.5M |
| Q4 2023 | 46 | $58.1M |
| Q3 2023 | 41 | $58.7M |
| Q2 2023 | 41 | $77.0M |
| Q1 2023 | 37 | $72.8M |
| Q4 2022 | 36 | $40.2M |
| Q3 2022 | 33 | $57.2M |
| Q2 2022 | 36 | $53.1M |
| Q1 2022 | 41 | $105.0M |
| Q4 2021 | 47 | $153.5M |
| Q3 2021 | 42 | $172.1M |
| Q2 2021 | 29 | $33.8M |
| Q1 2021 | 25 | $26.3M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding aTYR PHARMA INC; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Two Sigma Investments, LP | 1,144,565 | $892.8K | 0.00% | +690,122+151.9% | Added |
| Morgan Stanley | 1,225,467 | $955.9K | 0.00% | −177,542−12.7% | Reduced |
| Millennium Management LLC | 1,641,246 | $1.28M | 0.00% | +1,641,246 | New |
| Gsa Capital Partners LLP | 1,684,586 | $1.31M | 0.08% | −946,052−36.0% | Reduced |
| State Street Corp | 1,754,399 | $1.37M | 0.00% | +29,556+1.7% | Added |
| Geode Capital Management, LLC | 2,385,485 | $1.86M | 0.00% | +101,768+4.5% | Added |
| Vanguard Capital Management LLC | 3,812,132 | $2.97M | 0.00% | +3,812,132 | New |
| UBS Group AG | 3,867,213 | $3.02M | 0.00% | +2,241,916+137.9% | Added |
| BlackRock, Inc. | 6,443,904 | $5.03M | 0.00% | −105,795−1.6% | Reduced |
| Federated Hermes, Inc. | 10,509,678 | $8.20M | 0.01% | 00.0% | Unchanged |
| FMR LLC | 14,706,843 | $11.5M | 0.00% | +8,848+0.1% | Added |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −841,350−100.0% | Sold out |
| Tikvah Management LLC | 0 | $0 | 0.00% | −460,833−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −39,006−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −24,032−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −11,255−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −3,014−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −280−100.0% | Sold out |
| Rosalind Advisors, Inc. | 0 | $0 | 0.00% | −1,039,080−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |